Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing's Fountain Medical Raises $62 Million for Clinical CRO Services

publication date: Oct 25, 2019

Fountain Medical, a global clinical CRO headquartered in Beijing, raised $62 million in a Series D financing led by Goldman Sachs, with Lilly Asia Ventures a co-investor. Founded in 2007, Fountain Medical said it would use the proceeds to expand its offerings around the world. With the growth of biopharma development in China, the company offers global clinical CRO services to China and ex-China biopharmas. China's CRO industry is growing quickly, the company said, spurred by its adoption of global regulatory standards over the past few years. More details.....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital